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ABSTRACT  
Background: Primary mast cell activation syndromes (MCAS) are a group of disorders 
presenting with symptoms of mast cell mediator release.  
Objectives: To assess the effectiveness and safety of orally-administered H1-antihistamines 
in the treatment of primary MCAS compared with placebo and other pharmacologic 
treatments. 
Methods: We systematically searched five databases, three trial repositories and contacted 
an international panel of experts to identify published and unpublished trials, enrolling a total 
of 71 patients (63 adults).   
Results: 36 potentially relevant studies were identified. Of these, five crossover trials met 
the eligibility criteria.  Five of these studies were judged to be at moderate or high risk of 
bias. Two studies compared an H1-antihistamine with placebo, two compared two different 
H1- antihistamines, and one study compared H1- and H2-antihistamines with oral cromolyn 
sodium. Four of the five RCTs were historic (reported from 1983-93), small (enrolling 8-15 
patients), and used agents and/or dosing regimens that are now uncommonly used   in 
clinical practice (i.e. azelastine, chlorpheniramine, hydroxyzine and ketotifen).  The fifth trial, 
which enrolled 33 adults with cutaneous and systemic mastocytosis found four weeks of 
treatment with the second-generation H1-antihistamine rupatadine, compared with placebo, 
resulted in significant improvements in quality of life, symptom control (itching, wheals and 
flares, flushing, tachycardia, and headache, but not gastrointestinal symptoms), and 
reduction of itching and whealing after standardized skin provocation to elicit Darier’s sign.   
Conclusions:  There is an urgent need for large, well-designed, double-blind, placebo-
controlled randomized trials investigating the effectiveness, cost-effectiveness and safety of 
second-generation H1-antihistamines in treatment of primary MCAS.  
 
PROSPERO registration: CRD42014007518 
 
BACKGROUND 
Mast cell activation syndromes (MCAS) are a group of disorders that typically present with 
symptoms of mast cell mediator release such as itching, flushing, whealing, flaring, 
angioedema, tachycardia, headache, and gastrointestinal manifestations including 
abdominal pain and diarrhea. These disorders are diagnosed when symptoms of mast cell 
mediator release are recurrent, accompanied by an increase in mast cell-derived mediators, 
and responsive to treatment with mast cell-stabilizing medications or mediator-targeting 
medications.1-9 
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Criterion 1 for diagnosis states that the term MCAS should be applied when there are clinical 
signs of severe recurrent or chronic systemic mast cell activation.  
 
Criterion 2 for diagnosis of MCAS is met when an increase in mast cell mediators in biologic 
fluids can be documented. These mediators include tryptase, histamine, prostaglandin D2, 
leukotrienes (LTC4 and LTD4), platelet-activating factor, pro-inflammatory cytokines, 
chemokines, and others. Criterion 2 is typically met when the total tryptase level is elevated 
in serum obtained at baseline, for example, at least 24 hours after complete resolution of 
anaphylaxis symptoms. This criterion is also met when histamine levels are elevated in 
plasma or when histamine and its metabolite N-methylhistamine (or less commonly, the 
prostaglandin PGD2 metabolite 11-beta-PGF-2-alpha) are elevated in 24-hour urine.
1-10 
 
Criterion 3 for diagnosis of MCAS is met when symptoms such as itching, flushing, whealing, 
flaring, and angioedema are relieved by a mast cell-stabilizing medication such as cromolyn 
sodium that decreases mediator release, or by medications that prevent or reduce the effect 
of mediators that are released – for example, H1- and/or H2-antihistamines to mitigate the 
effects of histamine, and anti-leukotrienes to mitigate the effects of leukotrienes.1-9 Such 
medications are typically given in a stepwise fashion on a regular daily or twice-daily basis 
for a three to six month trial period. If a patient responds appropriately to this treatment, it 
helps to confirm the diagnosis of MCAS.1-9 
 
The proposed classification system of MCAS divides the syndromes into three categories: 
primary, secondary, and idiopathic.1-5 Primary MCAS include clonal disorders such as 
cutaneous mastocytosis or systemic mastocytosis, and monoclonal MCAS.1-8 Non-clonal 
MCAS also occurs.9 Secondary MCAS include allergic diseases, induced or chronic auto-
immune urticaria, and some chronic inflammatory and neoplastic disorders.1-5 Idiopathic 
MCAS includes not only idiopathic mast cell activation syndrome, but also idiopathic 
anaphylaxis, spontaneous urticaria, and idiopathic angioedema.1-5 In this review, we  focus 
only on primary MCAS and specifically on cutaneous mastocytosis, systemic mastocytosis, 
and monoclonal MCAS. An algorithm has been proposed to facilitate diagnosis and 
management of mastocytosis.10 
 
For more than three decades, H1-antihistamines have been consistently recommended for 
relief of symptoms in mast cell activation syndromes, including cutaneous and systemic 
mastocytosis. However, the volume and quality of evidence supporting this recommendation 
is unclear.11-17  
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H1-antihistamines are the most commonly used therapeutic intervention in MCAS. 
Approximately 40 medications in this class are available worldwide for oral administration.12 
Mastocytosis experts have typically recommended oral (old) first-generation, sedating H1-
antihistamines such as azelastine, chlorpheniramine, diphenhydramine, hydroxyzine and 
ketotifen for the prevention and treatment of symptoms.1,2,4,5 However, azelastine and 
ketotifen have never been approved for oral use by some regulatory agencies such as the 
United States Food and Drug Administration (US FDA) and consequently have never been 
introduced for clinical use in the US or in many other countries. Overall, first-generation H1-
antihistamines have been more commonly recommended than (newer) second-generation 
H1-antihistamines. Use of first-generation H1-antihistamines in any disorder is difficult to 
track because most, including chlorpheniramine and diphenhydramine, are widely available 
for over-the-counter purchase without a prescription and are also widely used for self-
medication of common allergic disorders such as allergic rhinitis and acute and chronic 
urticaria.  
 
Second-generation, non-sedating H1-antihistamines such as cetirizine, desloratadine, 
fexofenadine, levocetirizine, and loratadine have become widely available in the past 
decade, and even newer H1-antihistamines such as bilastine and rupatadine are now also 
available in many countries. Second-generation H1-antihistamines are therefore increasingly 
recommended over the older medications in this class for use in MCAS.3,8,9,11,12  
 
In this systematic review, we sought to investigate the effectiveness and safety of H1-
antihistamines in the management of primary MCAS. 
 
METHODS 
We conducted the review according to the methods recommended by the Cochrane 
Collaboration,18 and have in relation to reporting our findings followed the recommendations 
detailed in the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) guidelines.19 
 
Criteria for considering studies for this review 
Types of study 
We appraised the literature by looking only at the highest forms of evidence; i.e. randomized 
controlled trials (RCTs) which compared H1-antihistamines with placebo or other 
pharmacologic agents. However, since we anticipated a paucity of RCTs we also considered 
quasi-RCTs.  
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Types of participants 
We were interested in studies conducted in any patients, including neonates, infants, and 
children20 as well as adults diagnosed with primary MCAS (i.e. cutaneous mastocytosis, 
systemic mastocytosis, and monoclonal MCAS) according to the recently developed 
consensus criteria for MCAS.1 We stipulated that at least two of the three criteria for 
diagnosis of MCAS needed to be met, namely: 
• The presence of symptoms and signs relevant to severe recurrent or chronic 
systemic mast cell activation 
• A documented increase in a mast cell derived mediator such as serum tryptase or 
plasma or urine histamine 
• Response to treatment with one or more anti-mediator medications.4  
 
Types of interventions 
We included studies investigating the use of systemic H1-antihistamines (i.e. oral, 
intramuscular and intravenous administration). 
 
Types of outcome measures 
We stipulated the following primary and secondary outcome measures: 
 
Primary 
• Clinical improvement: prevention or resolution of symptoms as assessed by any 
objective measure. 
• Quality of life 
 
Secondary 
• Drug toxicity (adverse events)  
• Symptom scores 
• Number of hospital admissions 
• Duration of hospital admissions 
• Elevated serum tryptase levels (baseline) 
• Elevated plasma and urine histamine levels and 24-hour urine N-methylhistamine 
levels (baseline) 
• Cost-effectiveness. 
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Search methods for identification of studies  
We searched the following international electronic databases: The Cochrane Central 
Register of Controlled Trials (CENTRAL) to October 2013, The Cochrane Database of 
Systematic Reviews and Database of Abstracts of Reviews of Effects (DARE) to October 
2013, MEDLINE (Ovid SP, 1966 to October 2013), EMBASE (OVID SP, 1980 to October 
2013), CINAHL (EBSCO host, 1982 to October 2013), ISI Web of Science (1945 to October 
2013) (see Appendix 1). There were no language, publication year or publication status 
restrictions in our searches. In order to find on-going or unpublished studies we also 
searched three international trial repositories: www.clinicaltrials.gov; www.controlled-
trials.com; and www.anzctr.org.au and contacted four international subject experts. 
 
Data abstraction 
Two reviewers (UN and ER) independently scrutinized all titles and abstracts of articles 
generated by the search strategy detailed above and designated each study as either 
potentially included or excluded or unsure according to the agreed inclusion criteria. Both 
reviewers (UN and ER) then independently assessed the full manuscripts of all studies 
classified as potentially included. Consensus was achieved and no recourse to additional 
independent reviewers (FERS and AS) was needed. Data were then independently 
abstracted by both reviewers onto a customized data extraction sheet. The following data 
were extracted: authors; country and setting; year, participants (gender, mean age and 
range); description of intervention; outcome measures (primary and secondary); withdrawals 
and losses to follow-up; and adverse events. 
 
Quality assessment 
Critical appraisal of the included studies was performed independently by both reviewers 
(UN and ER). The methodological quality of the included RCTs and quasi-RCTs  was 
assessed using the methods detailed in section eight of the  Cochrane Handbook for 
Systematic Reviews of Interventions.18 We focused on using the following seven domains to 
assess quality: adequate sequence generation; allocation concealment; blinding of 
participants and personnel; blinding of outcome assessment; the addressing of incomplete 
outcome data; the absence of selective reporting and the absence of other sources of bias. 
Each parameter of included trial quality was graded: A – low risk of bias; B – moderate risk 
of bias; C – high risk of bias. Where differences existed the two authors (UN and ER) were 
able to agree on a consensus position without recourse to adjudication by other reviewers 
(FERS and AS). 
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Data synthesis 
There were insufficient comparable data to permit meta-analysis.  We therefore first 
undertook a descriptive summary of data and then undertook a narrative synthesis of the 
body of evidence uncovered. Had sufficient data been available, we planned to use Review 
Manager for data analysis and quantitative data synthesis. For dichotomous data, we 
planned to calculate individual and pooled statistics as relative risks (RR) with 95% 
confidence intervals (95% CI). For continuous data, we hoped to calculate individual and 
pooled statistics as mean differences (MD) and/or standardized means differences with 95% 
CI.  
 
We planned to consider if meta-analysis was appropriate in the presence of significant 
clinical or statistical heterogeneity. We planned to test for heterogeneity using the I2 statistic. 
Significant heterogeneity would have been assumed if the I2 was greater than 40% (i.e. more 
than 40% of the variability in outcome between trials could not be explained by sampling 
variation).21 If able to pursue a meta-analysis, we would have used fixed effect or random 
effects modeling depending on whether or not the data were found to be homogenous. In 
the absence of any substantial statistical or clinical heterogeneity, we planned to report a 
fixed-model derived pooled effect. We intended to conduct, wherever possible, quantitative 
analyses of outcomes on an intention-to-treat basis. We would then have assessed evidence 
of publication bias graphically using Funnel plots and statistically using Begg and Egger 
tests.22-23 In the event of statistical and clinical heterogeneity we had planned to undertake 
subgroup analyses based on: age of patient (neonate/infant, child and adult); type of 
mastocytosis; H1-antihistamine used; and the route of administration. 
 
RESULTS 
Our searches identified 36 potentially relevant papers, from which we identified five trials in 
which a total of 71 patients were enrolled (see Figure 1 PRISMA flow diagram). Four studies 
were RCTs that included 63 adult participants, and the remaining study was a RCT of eight 
children.13-17 The key characteristics of these trials are summarized in Tables 1a-c.   
Contacting experts and undertaking detailed searches of the bibliographies of included 
papers did not lead to identification of any additional studies.  
 
Quality assessment of these trials revealed that none were judged to be at low risk of bias 
(see Tables 2a-c).  Four RCTs were judged to be at moderate risk of bias;13,15-17 and the fifth 
was judged to be at a high risk of bias.14 
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A range of outcomes were seen across the trials (Tables 3a-c), but all considered the effect 
of H1-antihistamines on symptoms in patients with primary MCAS.  
 
Studies comparing H1-antihistamine against placebo 
Description of studies 
There were two trials investigating H1-antihistamines against placebo.  Both were conducted 
in adults with primary MCAS; in the first, ketotifen14  was evaluated and in the second 
rupatadine17 was studied (see Table 1a).   In the rupatadine trial, 33 patients were enrolled 
and a number of evaluations were performed.17 Firstly, the quality of life of participants was 
assessed using a validated instrument (ItchyQoL). Secondly, pruritus was measured using a 
validated 10cm visual analogue scale after standardised skin provocation testing to elicit 
Darier’s sign . Thirdly, symptoms including itching, flushing, whealing, flaring, tachycardia, 
headache and gastrointestinal manifestations were evaluated using a 5-point Likert scale 
(i.e. none, mild, moderate, severe and very severe). 
 
Main findings 
In the double-blind placebo-controlled crossover RCT of rupatadine, Siebenhaar et al. 
reported that four weeks of once daily rupatadine 20 mg significantly improved the mean 
total symptom specific quality of life (16.1% reduction in ItchyQoL; p=0.004), and resulted in 
significant improvement in the domains of symptoms (17.4% reduction; p=0.007), functions 
(10.6% reduction; p=0.022) and emotions (18.5% reduction; p=0.006). In three patients 
(10%), treatment with a rescue H1-antihistamine was required during the rupatadine phase 
compared with 8 patients (27%) during the placebo phase.17 A total of 40 treatment 
emergent adverse effects were reported by 28 participants; 20 during treatment with 
rupatadine and 20 with the placebo. The authors provided little detail about these adverse 
effects other than noting that none were deemed serious. 
 
In the small crossover RCT comparing ketotifen 2 mg twice daily for three months with 
placebo in 10 adults with urticaria pigmentosa, Czarnetzki et al.14  reported a significant 
reduction in pruritus and wheals; however, this study was judged to be at high risk of bias 
with little detail on how an adequate sequence was generated and whether the outcome was 
blinded; indeed, 40% of the patients experienced tiredness while taking ketotifen, which may 
have compromised allocation concealment. 
 
Summary of evidence 
We found limited evidence evaluating H1-antihistamines against placebo. One study was of 
poor methodological quality and therefore needs to be interpreted with caution.14 In contrast, 
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the findings of Siebenhaar et al.17 are promising and point to the likely effectiveness of H1-
antihistamines in adults with primary MCAS.  
 
Studies comparing H1-antihistamines 
Description of studies 
We found two crossover RCTs in this category (see Table 1b). In one small study  
undertaken in eight children with cutaneous mastocytosis, the first-generation H1-
antihistamines ketotifen and hydroxyzine were compared.15 This study was only of moderate 
quality as it was unclear how the random sequence was generated and how participants and 
investigators were blinded.15 In the second study in 15 adults with urticaria pigmentosa, the 
first-generation H1-antihistamine chlorpheniramine 12 mg twice daily was compared with the 
H1-antihistamine azelastine 4.4 mg or azelastine 8.8 mg twice daily and placebo twice 
daily.16 
 
Main findings 
In the pediatric study,15 hydroxyzine 2 mg/kg four times daily was found to be significantly 
more effective than ketotifen 1 mg three times daily in improving symptoms (p<0.05) 
especially flushing and abdominal pain (p=<0.01) The risk of sedation was similar with both 
agents (p>0.20).  
 
In the adults with urticaria pigmentosa, there was no significant difference between 
chlorpheniramine 12 mg bid and azelastine 4.4 mg or 8.8 mg bid in terms of overall symptom 
reduction;16 however, azelastine (4.4 mg dose) was more efficacious in reducing abdominal 
pain (p<0.01) and pruritus (both 4.4 mg and 8.8 mg doses) (p<0.05) and also at reducing the 
cutaneous wheal and flare response to histamine. Chlorpheniramine was associated with 
less fatigue than azelastine 8.8 mg. Additionally, two patients on azelastine dropped out of 
the trial because of the moderate-to-severe bitter metallic taste.  
 
Summary of evidence 
There was little evidence comparing different H1-antihistamines in the treatment of primary 
MCAS. Two published trials of moderate quality suggested that in children, hydroxyzine was 
more effective than ketotifen for symptom relief,15 and that in adults,16 azelastine and 
chlorpheniramine had comparable overall effectiveness, azelastine was more effective in 
relieving abdominal pain and pruritus.16  These H1-antihistamines caused varying degrees of 
sedation, which may or may not have affected allocation concealment and azelastine caused 
a bitter metallic taste. 
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Studies comparing H1-antihistamines against other pharmacologic agents 
Description of studies 
Only one study was found in this category: a placebo-controlled RCT in eight adults with 
systemic mastocytosis, in which treatment with the H1-antihistamine chlorpheniramine 4 mg 
administered with the H2-antihistamine cimetidine 200 mg, both given four times daily, were 
compared with cromolyn sodium 200 mg four times daily (see Table 1c).13 Little detail was 
provided on how the randomisation sequence was generated thereby introducing a 
moderate risk of bias. 
 
Main findings 
There was no difference in the individual symptom scores (p>0.05) of the participants 
between the two treatment regimens, nor was there a difference between patient and 
physician evaluations of disease status at the end of both cycles of treatment (p>0.50).13 
Three of the four patients with nausea improved on cromolyn sodium. Similarly, five of the 
six patients with pruritus and four of the six patients with urticaria improved with the co-
administration of an H1-antihistamine and an H2-antihistamine. There was no significant 
difference in adverse effects; fatigue was reported by five patients on cromolyn sodium and 
two on H1-/H2-antihistamines, and one patient on H1- and H2-antihistamines was withdrawn 
after mild liver function test abnormalities were identified.  
 
Summary of evidence 
There is little evidence comparing H1-antihistamines with other agents in the treatment of 
primary MCAS. The only published study demonstrated no overall significant difference in 
symptom control when an H1-antihistamine co-administered with an H2-antihistamine was 
compared with cromolyn sodium in eight patients.13 
 
DISCUSSION 
Despite H1-antihistamines being recommended and used in the management of primary 
MCAS,1-9,11 this systematic review clearly demonstrates that there is little high quality 
evidence to support this widely held orthodoxy. We identified four RCT published between 
1983 and 1993 in which study populations were small, ranging from 8-15 patients; in addition 
to the likely low power, a number of other methodological problems were identified. We did, 
however, identify one RCT published in 2013 that was of reasonably high quality and of 
reasonable size in the context of this body of literature.17 In this study of 33 adults with 
mastocytosis, the second-generation H1-antihistamine rupatadine was shown to be superior 
to placebo. A statistically significant improvement in the quality of life of participants, a 
significant reduction in whealing and itching on standardized skin provocation testing to elicit 
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Darier’s sign,  , and a significant reduction in symptoms (itching, flushing, tachycardia and 
headache), despite significantly less use of rescue medication, were all demonstrated. 
Moreover patients with the most severe symptoms appeared to derive the greatest benefit.  
Only gastrointestinal symptoms, which are due to the action of histamine at H2-receptors 
rather than H1-receptors, were not significantly improved. Interestingly, in two older 
studies,15,16 the H1-antihistamines hydroxyzine and azelastine were reported to reduce 
abdominal pain, despite the fact that  H2-antihistamine properties are not typically attributed 
to these medications.  
 
The strength of this systematic review lies in its sound methodology in that it was conducted 
to international standards by performing a comprehensive search of five electronic 
databases of published research without language restrictions, three international trial 
repositories, contacting international experts in this field, and searching the bibliographies of 
the studies identified. As far as we are aware, this is the first systematic review to have 
investigated the role of H1-antihistamines in the treatment of primary MCAS. 
 
The main limitations of this review relate to the small numbers of RCTs published from 1983-
2013, most of which were of poor or moderate quality due to small study sample sizes, 
heterogeneity of study populations and treatments studied, inconsistent descriptions of 
inclusion or exclusion criteria, inconsistent control arms, use of subjective outcome 
measures (some of which were not validated), and potential problems with allocation 
concealment. In addition, we were unable to conduct a meta-analysis because of the clinical 
and methodological heterogeneity of the participants studied.  
 
Owing to the limited available data, we are unable to make any confident recommendations 
regarding choice of H1-antihistamine or dosing; however, the findings from the one 
contemporary trial of moderately high quality suggest the urgent need for large, well-
designed, double-blind, placebo-controlled  randomized trials to investigate the use of this 
and other second-generation H1-antihistamines in the treatment of primary MCAS. Dose-
response studies are also needed, as up to four-fold doses of these second-generation H1-
antihistamines is now officially recommended worldwide in chronic spontaneous urticaria 
guidelines.24  
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 Figure 1: PRISMA flow diagram  
  
 
 
 
 
51 potentially relevant papers 
from 5 databases were identified 
15 duplications 
excluded 
31 papers defined as: 
• Conceptual     25  
• CCT      1 
• Cohort             1 
• Case series     4   
After de-duplication 36 potentially 
papers are included for screening 
Included 
(n=5) 
Web of 
Science 
18 
CINAHL 
 
5 
Cochrane 
Library  
3 
EMBASE 
 
 17 
MEDLINE  
 
8 
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Table 1a: Detailed characteristics of included studies comparing H1-antihistamines 
versus placebo 
Author & 
Year; 
Country 
 
Design Population 
(Age, Gender 
and 
Diagnosis) 
Intervention Outcome Notes 
Czarnetzki 
198314 
Germany 
Double-
blind, 
randomized,  
placebo-
controlled 
crossover 
study 
 
-10 adults; 6 
female 
-Urticaria 
pigmentosa 
 
Three 30 day 
treatment 
periods 
(1)  Ketotifen 
2 mg twice a 
day 
(2)  Placebo, 
twice a day. 
 
Daily patient 
record of 
pruritus and 
intensity of 
whealing 
(scale of 0-3) 
No details of 
washout 
period/process 
provided 
Siebenhaar 
201317 
Germany 
Double-
blind, 
randomized,  
placebo-
controlled 
crossover 
study 
 
- 33 adults (23 
female), 3 
females later 
excluded. 
- 20-70 y/o, 
mean age 49.4 
y. 
- 7 with 
chronic stable 
maculopapular 
cutaneous 
mastocytosis 
and 23 with 
indolent 
systemic 
mastocytosis 
and skin 
involvement. 
 
2 
consecutive 
28 day 
treatment 
periods (Min: 
25d, Max 
30d). 
(1) 
Rupatadine 
20 mg once 
a day 
(2) Placebo 
once a day 
Patients 
assessed at 
baseline and 
end of 4 
week 
treatment 
arms. 
(1) Patient 
evaluation of 
Quality of 
Life using 
validated 
ItchyQoL; 
questionnaire 
at the end of 
each 4 
weeks of 
treatment. 
(2) 
Standardized 
skin 
provocation 
testing to 
elicit Darier’s 
sign and 
assessment 
of pruritus 
severity 
using visual 
analog scale. 
(3) 
Evaluation of 
symptom 
severity 
using 5 point 
Likert scale. 
No details of 
washout 
period/process 
provided 
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Table 1b: Detailed characteristics of included studies comparing different types H1-
antihistamines 
Author & 
Year; 
Country 
Design Population 
(Age, Gender 
and 
Diagnosis) 
Intervention Outcome Notes 
Kettelhut 
198915 
USA 
Double-
blind, 
randomized,  
placebo 
controlled 
crossover 
trial 
- 8 children  (2 
female) 
- 1-8 y 
- Cutaneous 
mastocytosis; 
6 with  
urticaria 
pigmentosa, 2 
with diffuse 
cutaneous 
mastocytosis 
and increased 
mast cells in 
bone marrow 
aspirate, but 
normal bone 
marrow 
biopsy and no 
hepato-
splenomegaly.
 
2 consecutive 6 week 
trial arms consisting of 
a 2-week washout 
followed by a 4-week 
treatment period.  
(1) ketotifen liquid 1 
mg twice a day & 
hydroxyzine placebo 
four times a day. 
(2) hydroxyzine liquid 
2 mg/kg four times 
daily and ketotifen 
placebo twice daily. 
Patients 
assessed at 2 
week intervals 
(1) Plasma 
histamine levels, 
complete  blood 
count and  
biochemistry 
tests  
(2) Assessment 
of daily symptom 
diary (0-3) and 
side effects 
at beginning and 
end of each trial 
arm 
(3) 24 hr urine 
collection for 
quantitative 
urinary histamine 
and routine 
urinalysis. 
. 
Two 
consecutive 
6 week trial 
arms with 
the first two 
weeks 
serving as 
the washout 
period 
Friedman 
199316 
USA 
Double-
blind, 
randomized, 
three period 
crossover  
trial 
- 15 patients 
(10 female) 
- 25-65 y, 
mean age 
44.1 y 
- 15 had 
histologic 
evidence of 
mastocytosis 
(urticaria 
pigmentosa), 
15 had 
elevated 
plasma 
histamine 
levels, and 12 
had elevated 
number of 
bone marrow 
mast cells.
3 consecutive trial 
periods; comprising a 
2-week wash-out and 
a 4-week treatment 
period. 
(1) Chlorpheniramine, 
12 mg, twice a day 
(and 2 doses of 
placebo twice a day) 
(2) Azelastine, 4.4 mg 
twice a day (and  2 
doses of placebo twice 
a day) 
(3) Azelastine, 8.8 mg 
twice a day (and 2 
doses of placebo twice 
a day) 
2 week 
washout 
period 
following 
first two of 
three 
treatment 
periods in 
which no 
study drugs 
taken. 
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Table 1c:  Detailed characteristics of included studies comparing H1-antihistamines 
with different pharmacological therapies 
Author 
& Year; 
Country 
Design Population 
(Age, Gender 
and 
Diagnosis) 
Intervention Outcome Notes 
Frieri 
198513 
USA 
Double-
blind, 
randomized,  
double 
crossover 
trial 
- 8 adults (7 
female) 
- 33-65 y 
- Systemic 
mastocytosis; 
7 had urticaria 
pigmentosa, 6 
had elevated 
bone marrow 
mast cells, 7 
had 
abnormalities 
on bone scans 
and 6 had 
hepato-
splenomegaly. 
2 consecutive 10 
week treatment 
periods. 
(1) Cromolyn 
sodium 200 mg by 
mouth four times 
a day + 
chlorpheniramine 
and cimetidine 
placebos four 
times a day. 
 
(2) 
chlorpheniramine 
4 mg four times a 
day + cimetidine 
300 mg four times 
a day + cromolyn 
sodium placebo 
four times a day. 
 
Patients 
evaluated at 
5 week 
intervals. 
(1) Plasma 
and urine 
histamine 
levels. 
(2) Complete 
blood count, 
liver function 
tests 
(3) 
Urinalysis 
(4) Patient 
and 
physician 
assessment 
of disease 
status; using 
numerical 1-
5 scale. 
(5) Patient 
symptom 
diary (0-4 
scale) 
2 
consecutive 
10 week 
treatment 
periods with 
a 2 week 
washout 
and 
crossover 
period at 
end of week 
10. 
 
 
 
A
cc
ep
te
d
 A
rt
ic
le
 
Table 2a: Risk of bias of included studies comparing H1-antihistamines with placebo 
Author 
& year 
Adequa
te 
sequen
ce 
generati
on 
Allocatio
n 
concealm
ent 
 
Blinding 
of 
participa
nts and 
personn
el 
Blinding 
of 
outcome 
assessm
ent 
 
Incompl
ete 
outcome 
data 
address
ed?  
 
Free of 
selecti
ve 
reporti
ng 
 
Fre
e of 
oth
er 
bia
s 
Gra
de 
Czarnet
zki  
198314 
Unclear 
 
Yes 
 
Yes 
 
Unclear  
 
Unclear 
 
Yes 
 
Yes C 
Siebenh
aar 
201317 
Yes 
 
Unclear 
 
Yes Unclear 
 
Yes 
 
Yes Yes B 
 
 
Table 2b: Risk of bias of included studies comparing different H1-antihistamines 
Author 
& year 
Adequat
e 
sequen
ce 
generati
on 
Allocatio
n 
concealm
ent 
 
Blinding 
of 
participa
nts and 
personn
el 
Blinding 
of 
outcome 
assessm
ent 
 
Incomple
te 
outcome 
data 
addresse
d?  
 
Free of 
selecti
ve 
reporti
ng 
 
Fre
e of 
oth
er 
bia
s 
Gra
de 
Friedm
an 
199316 
Yes 
 
Yes 
 
Unclear 
 
Unclear 
 
Yes 
 
Yes 
 
Yes B 
Kettelh
ut 
198915 
Unclear 
 
Yes 
 
Unclear 
 
Yes 
 
Yes 
 
Yes Yes B 
 
 
Table 2c: Risk of bias of included studies comparing H1-antihistamines with other 
pharmacological therapies 
Auth
or & 
year 
Adequat
e 
sequenc
e 
generati
on 
Allocation 
concealm
ent 
 
Blinding 
of 
participa
nts and 
personne
l 
Blinding 
of 
outcome 
assessm
ent 
 
Incomple
te 
outcome 
data 
addresse
d?  
 
Free of 
selecti
ve 
reporti
ng 
 
Fre
e of 
oth
er 
bias 
Gra
de 
Frieri 
19851
3 
Unclear 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes B 
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Table 3a: Summary of main findings of included studies comparing H1-antihistamines 
with placebo 
Author & year Main Findings 
Czarnetzki 
198314 
- 2 patients withdrew; 1 because of urgent 
eye surgery and 1 because of pregnancy. 
- Statistically significant symptom reduction 
with ketotifen; p< 0.025 (whealing) and p< 
0.010 (pruritus) 
- 40% of participants experienced mild to 
moderate tiredness with ketotifen. 
Siebenhaar 
201317 
- 2 participants withdrew. One experienced 
severe bone pain while taking the placebo. 
The second experienced fatigue during 
rupatadine therapy. 
- 1 participant was withdrawn because of 
non- compliance. 
- 28 participants reported 40 treatment-
emergent adverse effects; 20 with placebo 
and 20 with rupatadine; none considered 
severe. 
- Significant improvement in mean total 
ItchyQol score with rupatadine; 16.1% 
reduction p<0.004. Also statistically 
significant reduction in scores for the 
domains of symptoms, functions and 
emotions (17.4%, 10.6% and 18.5%, 
respectively). Those patients with a higher 
ItchyQoL total score, that is, poorer quality of 
life, received more benefit from rupatadine.  
- Significant reduction in Visual Analog Score 
for pruritus and whealing after standardized 
skin provocation testing to elicit Darier’s sign   
during rupatadine treatment compared with 
placebo; 30.3% reduction p= 0.041. 
- Significant improvement in day-to-day 
itching, whealing, flaring, flushing, 
tachycardia, and headache, but not GI 
symptoms p>0.05. 
- Fewer patients required rescue therapy 
during rupatadine treatment; 3 (10%) versus 
8 (27%). 
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Table 3b: Summary of main findings of included studies comparing different H1-
antihistamines 
Author & year Main Findings 
Kettelhut 
198915 
- 1 participant unable to complete final 2 weeks 
of second arm of trial. Authors judged sufficient 
data collected to include in final analysis. 
- Hydroxyzine was significantly more 
efficacious than ketotifen at reducing symptom 
scores; p<0.05. 
- Symptoms of flushing and abdominal pain 
were the most likely to improve with 
hydroxyzine; p<0.01. 
- No significant differences in plasma or urine 
histamine levels following treatment with either 
therapy 
- No significant difference in risk of sedation 
between the 2 agents; p >0.20 
- Results of serum haematological and 
biochemical testing not reported. 
Friedman 
199316 
- 3 withdrawals: 1st withdrew on day 9 of 
second period with disease exacerbation that 
was considered unrelated to the study. 2 
participants   withdrew while taking azelastine, 
complaining of a severe bitter metallic taste. 
- Azelastine statistically superior at reducing 
wheal and flare response to intradermal 
histamine and morphine sulphate. 
- Mean plasma histamine levels reduced by 
both azelastine and chlorpheniramine, no 
statistical difference between the two agents. 
- No statistically significant difference between 
azelastine and chlorpheniramine in terms of 
overall symptom reduction and patient and 
physician global evaluation. However, 
azelastine significantly reduced pruritus and 
abdominal pain when compared to 
chlorpheniramine (p<0.05 and p<0.01). 
- Chlorpheniramine statistically associated with 
less fatigue (p<0.05).
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Table 3c: Summary of main findings of included studies comparing Ha-antihistamines 
with other pharmacological agents 
Author & year Main findings 
Frieri 
198513 
- 2 patients on cromolyn sodium withdrew: 1st 
experienced severe generalized pruritus and 
dizziness after 24 hours. 2nd experienced 
disease exacerbation (predominant symptoms 
of flushing and nausea) and withdrew after 7 
days. 
- 1 patient developed mild liver function test 
abnormalities after 5 weeks of H1- and H2-
antihistamine treatment. 
- 5 patients complained of fatigue (2 with H1- 
and H2-antihistamines, 3 with cromolyn 
sodium) 
- No statistically significant difference in patient 
symptom scores (assessed using a daily 
diary), between cromolyn sodium and 
combined H1- and H2-antihistamine therapy: 
mean symptom scores 3.1 versus 3.2, 
respectively. 
- 3 of 4 patients with nausea improved with 
cromolyn sodium. 5 of 6 patients suffering 
from pruritus improved with H1- and H2-
antihistamine therapy. 4 of 6 patients with 
urticaria improved with H1- and H2-
antihistamine therapy. 
- No significant differences in patient and 
physician assessment of disease status. 
- No significant change in plasma or urine 
histamine levels following either treatment. 
 
 
Appendix 1 
Search strategy: MEDLINE format 
 
1. Mastocytosis, Cutaneous/ or Mastocytosis.mp. or Mastocytosis/ or Mastocytosis, 
Systemic/ 
2. urticaria pigmentosa.mp. or Urticaria Pigmentosa/ 
3. teleangiectasia macularis eruptiva perstans.mp. 
4. monoclonal mast cell activation syndrom*.mp. 
5. 1 or 2 or 3 or 4 
6. MIANSERIN/ or METHAPYRILENE/ or FLUNARIZINE/ or CINNARIZINE/ or 
TERFENADINE/ or LORATADINE/ or ASTEMIZOLE/ or CETIRIZINE/ or DOXEPIN/ or 
PROMETHAZINE/ or TRIPELENNAMINE/ or PYRILAMINE/ or ANTAZOLINE/ or 
DOXYLAMINE/ or DIPHENHYDRAMINE/ or DIMENHYDRINATE/ or CLEMASTINE/ or 
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This article is protected by copyright. All rights reserved. 
KETOTIFEN/ or CYPROHEPTADINE/ or MECLIZINE/ or HYDROXYZINE/ or CYCLIZINE/ or 
TRIPROLIDINE/ or PHENIRAMINE/ or DIMETHINDENE/ or BROMPHENIRAMINE/ or 
CHLORPHENIRAMINE/ or exp Histamine H1 Antagonists/ or (Neoclarityn or Telfast or Xyzal 
or Mizollen or Vallergan or Dimotane or Piriton or Periactin or Periactin or Tavegil or Ucerax 
or Atarax or Phenergan or Zaditen or Otrivine-Antistin or Valoid or tritoqualine or Tranilast or 
temelastine or proxicromil or protopine or picumast or NCO 650 or mirtazapine or 
mequitazine or lodoxamidetromethamine or dexchlorpheniramine or chloropyramine or 
carebastine or Actifed or Mianserin or Methapyrilene or Flunarizine or Cinnarizine or 
Epinastine or Emedastine or Azelastine or Terfenadine or Olopatadine or Mizolastine or 
Loratadine or Levocabastine or Fexofenadine or Ebastine or Desloratadine or Astemizole or 
Levocetirizine or Cetirizine or Acrivastine or Alimemazine Tartrate or Doxepin or 
Promethazine or Methdilazine or Tripelennamine or Pyrilamine or Antazoline or 
Phenyltoloxamine or Doxylamine or Diphenhydramine or Dimenhydrinate or Clemastine or 
Carbinoxamine or Ketotifen or Diphenylpyraline or Cyproheptadine or Azatadine or 
Oxatomide or Meclizine or Hydroxyzine or Cyclizine or Buclizine or Triprolidine or 
Pheniramine or Dimethindene or brompheniramine or Chlorpheniramine or antihistamin$ or 
Benadryl or Livostin direct or opatanol or emadine or relestat or optilast or nytol or dreemon 
or medinex or nightcalm or panadolnight or clarityn allergy or nyquil or sinequan or xepin or 
pbz-sr or tacaryl or hismanal or kestine or ebastel or clistin or dramamine or tussirex or 
antivert or tinsetped or optimine or stugeron or stugeron forte or sibelium or histadyl or 
polaramine or alomide or rizaben).mp. 
7. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or 
placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans 
and animals)).sh. 
8. 5 and 6 and 7 
 
Search strategy: free-field format 
 
(mastocytosis or systemic mastocytosis or cutaneous mastocytosis or monoclonal mast cell 
activation syndrome) 
And 
(Histamine H1 antagonists or Neoclarityn or Telfast or Xyzal or Mizollen or Vallergan or 
Dimotane or Piriton or Periactin or Periactin or Tavegil or Ucerax or Atarax or Phenergan or 
Zaditen or Otrivine-Antistin or Valoid or tritoqualine or Tranilast or temelastine or proxicromil 
or protopine or picumast or NCO 650 or mirtazapine or mequitazine or lodoxamide 
tromethamine or dexchlorpheniramine or chloropyramine or carebastine or Actifed or 
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This article is protected by copyright. All rights reserved. 
Mianserin or Methapyrilene or Flunarizine or Cinnarizine or Epinastine or Emedastine or 
Azelastine or Terfenadine or Olopatadine or Mizolastine or Loratadine or Levocabastine or 
Fexofenadine or Ebastine or Desloratadine or Astemizole or Levocetirizine or Cetirizine or 
Acrivastine or Alimemazine Tartrate or Doxepin or Promethazine or Methdilazine or 
Tripelennamine or Pyrilamine or Antazoline or Phenyltoloxamine or Doxylamine or 
Diphenhydramine or Dimenhydrinate or Clemastine or Carbinoxamine or Ketotifen or 
Diphenylpyraline or Cyproheptadine or Azatadine or Oxatomide or Meclizine or Hydroxyzine 
or Cyclizine or Buclizine or Triprolidine or Pheniramine or Dimethindene or brompheniramine 
or Chlorpheniramine or antihistamin* or Benadryl or Livostin direct or opatanol or emadine or 
relestat or optilast or nytol or dreemon or medinex or nightcalm or panadolnight or clarityn 
allergy or nyquil or sinequan or xepin or pbz-sr or tacaryl or hismanal or kestine or ebastel or 
clistin or dramamine or tussirex or antivert or tinset ped or optimine or stugeron or stugeron 
forte or sibelium or histadyl or polaramine or alomide or rizaben) 
And  
(random* or placebo or multicenter or prospective) or ((controlled or clinical) SAME trial*) or 
((single or double or triple or treble) SAME (mask* or blind*)) 
 
 
